Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Astellas, Otsuka, Meiji Joining Workplace Vaccination Campaign
The Japanese government’s workplace vaccination initiative for COVID-19 is drawing a growing list of companies from the pharmaceutical sector, with Astellas Pharma and the Otsuka group among the latest to reveal their intentions to take part in the campaign. Astellas…
To read the full story
Related Article
- Bristol Myers Kicks Off COVID-19 Inoculation Program, Eliminates Cost Burden on Employees
July 8, 2021
- Astellas Begins COVID-19 Vaccination Program
July 5, 2021
- Otsuka Group Takes the Lead to Launch Workplace Vaccination as Industry Peers Set to Follow
June 22, 2021
- Bristol Myers, Other Pharma Players Moving to Join Workplace Vaccination Campaign
June 7, 2021
BUSINESS
- Sanofi Files Venglustat for Gaucher Disease in Japan
June 29, 2026
- Toho Shareholders Approve Trigger for 3D Defense Measures
June 29, 2026
- Nippon Shinyaku Bags Option on Elixirgen’s DMD Candidate
June 29, 2026
- UK Accepts Taletrectinib Filing for ROS1+ NSCLC: Eisai
June 29, 2026
- Takeda Files XFG-Adapted COVID Vaccine in Japan
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…